Abbott - Biotech Market Share Report

Abbott market share report graphic featuring humira and synagisCompany: Abbott
2007 Sales: $3.1 billion
Market share: 4.2 $
CAGR: 119.1%

What they have: Abbott has two biotech blockbusters on the market. Humira, a monoclonal antibody, competes with Remicade and Enbrel. It's approved for rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, and plaque psoriasis. Synagis treats respiratory syncytial virus, the leading cause of hospitalization in babies under a year.

What to look for: Abbot is exploring new indications for Humira. It's also advancing a new biologic for autoimmune diseases. ABT-847 is in late-stage development for psoriasis and Crohne's disease. In addition, Abbott teamed up with Genentech in 2007 to develop and commercialize ABT-263 and ABT-869. ABT-263 is being tested in cancers and ABT-869 suppresses tumor growth by preventing the growth of new blood vessels that supply the tumor with oxygen and nutrients.

Abbott - Biotech Market Share Report
Read more on

Suggested Articles

Horizon Therapeutics is expanding its U.S. footprint to the Bay Area—the company unveiled a new R&D and manufacturing site in South San Francisco.

Azeria Therapeutics has raised £32 million ($41 million) to take its estrogen receptor positive breast cancer program into the clinic.

Biogen’s Al Sandrock has given a bullish assessment of Alzheimer’s disease drug aducanumab. The head of R&D at Biogen thinks the drug works, despite i